VAKCINA

boomer crook wrote:

Marius Lăcătuș wrote:

ajde ne preteruj, nisu tvoji slušali pixies

ja sam slusao pixies i jos upoznao nekog amera iz bostona i sokirao se sto on ne zna ko je frank black jel sam mislio, autosovinista kakav jesam, da tamo svi znaju za njih i samo to pice.

San Saba Songbird wrote:mislim ZAISTA ti ne treba nikakav napor da slušaš Pixies.

bemty wrote:

ćaća wrote:
 
Association da, causality ne mogu još da utvrde, nemaju dovoljno podataka. Svejedno incidencija nije visoka. Proplematično je to što je MHRA prijavila sličan broj reakcija na 20 miliona vakcinisanih kao i Nemci na 2 miliona. To znači ili da Britanci kriju podatke ili ih neadekvatno prikupljaju.

Uzgred, po standardnoj Yellow Card metodologiji prikupljanja podataka o ADR, uhvati se možda 10% slučajeva.

u britaniji je AZ mnogo vise rasporedjena po demografskim kategorijama. u nemackoj je nisu jedno vreme davali starijima od 65, a medju mladjima su imali prioritetne grupe u koje su upadali i zaposleni u skolama (mahom zene) i jos jedna profesija koje ne mogu sad da se setim... uglavnom, ako je veci deo problema prisutan kod mladjih zena, a u Nemackoj su uglavnom pelcovali mladje zene ovom vakcinom, moguce je da je problem tamo bio vidljiviji. takodje je moguce, posto se radi o izuzetno retkom dogadjaju, da se radi i o genetskim predispozicijama koje su u nekim regijama prisutnije. nhs prikuplja podatke vrlo priljezno i jako bi me cudilo da se nesto krije na nivou drzave. prosto mislim da ne bi moglo da prodje, da ne bi imao ko da spreci objavljivanje u medicinskim casopisima.

We first determined the serum neutralizing-antibody titer against wild-type pseudovirus...
Notably, undetectable neutralization titers were seen in 4 of 34 convalescent serum samples, in 6 of 25 BBIBP-CorV serum samples, and in 4 of 25 CoronaVac serum samples.

We next assessed the neutralizing activity of convalescent serum and vaccinee serum against D614G, B.1.1.7, and B.1.351 variants as compared with wild-type pseudovirus...
For the BBIBP-CorV vaccinee serum samples, although the GMTs of neutralization against the variants were not significantly different from the GMTs against the wild-type virus, 20* serum samples showed complete or partial loss of neutralization against B.1.351...
B.1.1.7 showed little resistance to the neutralizing activity of convalescent or vaccinee serum, whereas B.1.351 showed more resistance to the neutralization of both convalescent serum (by a factor of 2) and vaccinee serum (by a factor of 2.5 to 3.3) than the wild-type virus. Most of the vaccinee serum samples that were tested lost neutralizing activity

The Washington State Department of Health (DOH) is investigating reports of people in the state who tested positive for COVID-19 more than two weeks after being fully vaccinated. Scientists call these “vaccine breakthrough” cases, which are expected with any vaccine.
Large-scale clinical studies found that COVID-19 vaccines reduced the risk of getting COVID-19 in vaccinated people by up to 95% compared to people that did not receive the vaccine. However, the vaccines are not 100% effective in preventing infection. This means a small percentage of fully vaccinated people can be expected to still get COVID-19. These are identified as breakthrough cases.
Out of one million fully vaccinated individuals in Washington state, epidemiologists report evidence of 102 breakthrough cases since February 1, 2021, which represents .01 percent of vaccinated people in Washington. Breakthrough cases have been identified in 18 counties. The majority of those in Washington state with confirmed vaccine breakthrough experienced only mild symptoms, if any. However, since February 1, eight people with vaccine breakthrough have been hospitalized. DOH is investigating two potential vaccine breakthrough cases where the patients died. Both patients were more than 80 years old and suffered underlying health issues.

Hans wrote:Nova istraživanja pokazuju da zaštita od kovida uz pomoć Modernine vakcine traje najmanje šest meseci, preneo je AP.



U današnjem izveštaju Nju Ingland Džornal of Medisin navodi ono što je Fajzer naveo prošle nedelje o svojoj vakcini, a to je da i Modernina vakcina radi po istom principu.


Oba izveštaja, kompanija Fajzer i Moderna, baziraju se na testovima na više desetina ljudi koji su primili vakcinu tokom studija koje su prethodile masovnoj imunizaciji.


Međutim, te studije su urađene pre pojave novih, zaraznijih sojeva, zbog čega odvojeni izveštaj u medicinskom žurnalu piše o zabrinutosti zbog mutiranih tipova kovida.


Fajzer i Moderna su saopštili da rade na ažuriranju njihovih vakcina ili mogućnosti davanja još jedne doze, ukoliko bude potrebna protiv novih sojeva.


(b92)


Ovo je baš kratko vreme delovanja. Pritom, moj nereprezentativni uzorak od četvoro prekookeanaca kaže da Moderna ima jake nuspojave, slične onima koje opisuju ljudi koji su primili AZ.


Samo... jak im uzorak.

U Srbiji je do sada dato više od 2.650.000 vakcina, od čega je 1.120.000 građana primilo i drugu dozu.

Govoreći o vakcinaciji stranaca u Srbiji, Jovanović je rekao da je do sada vakcinisano njih 39.000.

"Very Stressed, To Put It Frankly": Adar Poonawalla On Vaccine Supply

India has administered around 8.3 crore [83 million] vaccine doses since the drive began on January 16, the Health Ministry said at a briefing on Tuesday evening

New Delhi: Existing production capacity to manufacture Covishield, one of the two Covid vaccines being administered in India is "very stressed, to put it frankly", Serum Institute of India (SII) CEO Adar Poonawalla told NDTV on Tuesday evening.
Mr Poonawalla said the SII - which produces between 60 and 65 million doses per month presently, has so far given around 100 million doses to the centre and exported 60 million - but is "still short of being able to supply to every Indian" who needs the vaccine.
"The globe needs this vaccine... we are prioritising the needs of India (but) we are still short of being able to supply to every Indian," Mr Poonawalla said.
He said SII needed ₹ 3,000 crore [340 million euros] - a shortfall linked to the deal with the government to sell a doses at a heavy discount - in order to ramp up capacity needed to scale up production by June.
"We're supplying in India at approximately ₹ 150-160 [1.7-1.8 euros]. The average price is around $20 (Rs 1,500) [17 euros]... (but) because of the Modi government's request, we are providing at subsidised rates... It is not that we're not making profits... but we are not making super profits, which is key to re-investing," he said.
"This (the amount needed) would be roughly ₹ 3,000 crores [340 million euros]. The process takes 85 days, so it would be just under three months before we scale up operations," he said, adding that he had written to the centre on this subject, failing which SII would approach the banks for a loan.
Mr Poonawalla said that even if SII could increase its capacity - to around 100 million doses per month - India needed other manufacturers to also scale up in order to meet requirements.
He also said export bans - last month the centre said it was pausing major Covishield shipments - and the 'first claim' deal with India were difficult to explain abroad, where it is sold at a substantially higher cost per dose.
Last week the centre said there was no outright ban on the export of vaccines.
The SII chief also said he was working towards making Russia's Sputnik-V, which is expected to get permission for use in India any day. He also said that Codagenix would enter trials soon.
"Codagenix is going to be a single-dose nasal vaccine that is a potential gamechanger... will take time to develop.. we have to make sure the delivery mechanism delivers just the right amount of vaccine around the mucosa to prevent the virus from entering the system," Mr Poonawalla explained.
"We're hoping it becomes super convenient to administer and also cuts transmission when you do get infected... that's the advantage of the nasal vaccine," he said.
The introduction of multiple vaccines in India will help speed up vaccination - a critical point given the renewed spread of the virus and calls to widen the vaccine net.
India has administered around 8.3 crore [83 million] vaccine doses since the drive began on January 16.
The centre has said the pace of the rollout is second only to the United States - 79.11 million been vaccinated in 79 days (as on April 4) compared to 165.05 million in 112 days by the US.
However, the alarming rate at which new cases are being reported every day means the vaccination effort has to be significantly faster to stop the virus from spreading.
The Chief Ministers of Delhi, Maharashtra and Punjab, as well as the Indian Medical Association, have all asked Prime Minister Narendra Modi to allow more people to be vaccinated.
At present, only those over 45, and healthcare and frontline workers, are eligible to get the shot.
The centre on Tuesday rejected calls to allow more people to get vaccinated, saying the focus had to be on vaccinating those who needed it and not on those who wanted the shot.
"We have to focus on Covid-appropriate behaviour and containment. When the time comes to open it to all, then we will," Dr VK Paul, a member of government think tank NITI Aayog, said.

"A game-changer" according to scientists involved.

Trials are starting on a nasal spray which could be 99.9% effective at killing coronavirus.

Virologists at @ASPHFT think it could potentially treat people up to 4 days after infection.

Exclusive access for @itvlondon. pic.twitter.com/SIOcWPdHny

— Sam Holder (@samholdertv) January 21, 2021

Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hourshttps://t.co/TDFdrP4Uwu

— Achyutha (@achyutha) April 7, 2021

Israel, NZ give interim approval for sale of coronavirus nasal spray, says company https://t.co/kaR22vwMEd

— ST Foreign Desk (@STForeignDesk) March 23, 2021